



Eurofins announces the success of its tender offers on three of its existing bonds

19 May 2021

Eurofins Scientific (EUFI.PA, rated Baa3 by Moody's and BBB- by Fitch, "Eurofins"), a global leader in bioanalytical testing announces today the results of the tender offers (the "Tender Offers") in respect to its EUR 353.6M 3.375% Bonds (ISIN: XS1268496640) due 30 January 2023 (the "2023 Bonds"), EUR 650M 2.125% Bonds (ISIN: XS1651444140) due 25 July 2024 (the "2024 Bonds") and its EUR 600M 3.75% (ISIN: XS2167595672) due 17 July 2026 Bonds (the "2026 Bonds", and together with the 2023 Bonds and the 2024 Bonds, the "Existing Bonds")

As of the expiration deadline (18 May 2021, 5pm CET), Eurofins had received valid tenders of EUR 894.6M in aggregate principal amount of the Existing Bonds.

Eurofins has decided to accept for purchase (all amounts in EUR):

Bonds	Current Outstanding	Bonds Validly Tendered	Bonds Accepted for Purchase	Remaining Outstanding
2023 Bonds	353,609,000	186,078,000	186,078,000	167,531,000
2024 Bonds	650,000,000	410,806,000	202,248,000	447,752,000
2026 Bonds	600,000,000	297,752,000	297,752,000	302,248,000
Total		894,636,000	686,078,000	

As announced on 11 May 2021, amounts accepted for the 2024 Bonds and 2026 Bonds are capped at EUR 500m.

Settlement of the purchase is expected to take place on 20 May 2021 (the "Settlement Date").

As previously communicated and following the Settlement Date, Eurofins intends to redeem in full the 2023 Bonds by exercise of the make-whole clause, de facto repurchasing all those bonds before end of June 2021.

With the success of the Tender Offers and the exercise of the make-whole clause on the 2023 Bonds, combined with the other amounts of senior gross debt repaid since January 2021, Eurofins will have reduced its corporate

senior gross debt by almost EUR 500M, while increasing its average life by more than 2.7 years (from 3.95 years to 6.68 years) and decreasing its average cost from currently 2.52% to 1.78% in 2022.

Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.

Notes to Editors:

For more information, please visit www.eurofins.com or contact:

Investor Relations
Eurofins Scientific SE
Phone: +32 2 766 1620
E-mail: ir@eurofins.com

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing and in agrosience Contract Research Organisation services. Eurofins is one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and in the support of clinical studies, as well as having an emerging global presence in Contract Development and Manufacturing Organisations. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With over 50,000 staff across a decentralised and entrepreneurial network of more than 800 laboratories in over 50 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

The Group's objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.

In 2020, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has carried out over 15 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments during COVID-19.

Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific's management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantees can be made as to their completeness or validity.